Irritable Bowel Syndrome Clinical Trial
Official title:
Multicenter Trial of Functional Bowel Disorders
The primary purpose for this study is to compare clinical treatments for patients with
functional bowel disorders (irritable bowel syndrome, abdominal pain, painful constipation)
in women. We also plan to: 1) determine what clinical features (medical or psychological)
determine which patients will improve to these treatments, and 2) understand if there are
any physiological features that relate to improvement in symptoms and response to the
treatments.
We will compare a psychological treatment (cognitive-behavioral therapy - CBT) with
education/attention placebo, and an antidepressant drug (desipramine) with a pill placebo.
This is the first large-scale study designed to determine the therapeutic effects of these
methods, and to also determine interactions among physiologic measures, psychologic and
sociodemographic factors, severity of symptoms, and therapeutic improvement including
quality of life.
Female patients (aged 18-65) with FBD (irritable bowel syndrome, painful constipation and/or
functional abdominal pain) will be enrolled at UNC-Chapel Hill and Toronto, Canada. A
severity index will determine recruitment into the group of moderate FBD (200 patients) and
severe FBD (100 patients). Each group will be randomized into the three treatment arms
(cognitive-behavioral treatment, desipramine, and education/attention placebo), treated over
a 12-week period, and followed for one year. Outcome measures will include symptoms
(standardized abdominal pain, stool form and frequency) using diary cards, daily functional
status (Sickness Impact Profile), depression (HAM-D) and psychological distress (SCL-90),
physiological measures (enhanced rectal motility and visceral sensation), and health care
use. Multivariate statistical methods with a hierarchical design will be applied to the data
to assure maintenance of statistical power over multiple tests of overlapping groups.
The results of this study should significantly improve our understanding of this complicated
syndrome that lowers the quality of life and economic productivity of large numbers of
women. The clinical impact of the study, in providing physicians with scientific evidence of
the efficacy of treatments of FBD that are commonly used in practice, is significant. We
anticipate that this study will provide clinicians with predictors of success among types of
FBD patients and types of therapy that will improve symptoms and quality of life, and reduce
the health care costs associated with this common syndrome while improving patient-physician
satisfaction.
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |